Moderate to severe vasomotor symptoms (VMS) affect a substantial proportion of menopausal patients and, for many, persist longer than previously recognized. While VMS are traditionally defined by hot flashes and night sweats, the overall symptom burden of menopause may also include sleep disruption, mood changes, cognitive concerns, and impacts on daytime functioning, all of which frequently contribute to clinical visits and broader quality of life discussions.

Hormone therapy remains an appropriate and effective option for selected patients, particularly those early in the menopausal transition. However, management decisions increasingly reflect clinical complexity. Cardiometabolic risk factors, prior hormone-sensitive malignancy, hepatic considerations, and patient preference all play an important role in therapeutic planning.

Emerging literature has drawn attention to potential associations between persistent VMS, sleep disturbance, and cardiometabolic risk markers, although causal pathways remain under investigation. These findings are expanding the clinical lens through which symptom burden is viewed and may influence long-term management discussions.

At the same time, nonhormonal management continues to evolve. Established options—including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and clonidine—remain relevant, particularly when comorbid depression, anxiety, neuropathic pain, or hypertension coexist. More recently, centrally acting therapies that modulate hypothalamic neurokinin signaling have emerged as menopause-specific, mechanism-based alternatives for the treatment of vasomotor symptoms in patients who cannot—or choose not to—use estrogen. As with any systemic therapy, thoughtful patient selection and appropriate monitoring remain important considerations.

As the therapeutic landscape broadens, menopause care may be shifting toward more individualized, mechanism-informed treatment strategies rather than a single default pathway, allowing clinicians to tailor approaches based on symptom profile, comorbidities, and patient values.

How has your approach to managing moderate to severe VMS evolved in recent years? When counseling patients, how do you balance symptom relief with broader health risk considerations? Where do emerging nonhormonal therapies fit within your current strategy?